Loading…
Loading…
can you comment on the trends you're seeing in the first line? Are you seeing a steady number of naive starts or an acceleration
Which programs are you most excited about, or do you think are the most de-risked? And then a second question, you mentioned for the U.S., you expect a mid-single-digit net price decrease in 2026. ...
Should we think of this cadence of new starts continuing in 3Q and beyond
what are you seeing in terms of the use of the first injection free versus those going straight to paid drug
how would you characterize the mix of growth in the TTR guidance from polyneuropathy versus cardiomyopathy
how is the enrolment in the IDEAL study in the partial UDCA responders going
Can you elaborate a bit more on sort of the half of the single patient prescribers in 2025 that have not written an additional script in Q1?
Curious what your expectations are for timing for data from RCC and muscle invasive bladder cancer
how you are thinking about the European COVID vaccination market and how you see the vaccination rate and pricing evolving there
how do you see the mix between retail and
can you comment a little bit more on how the progress in the real-world evidence generation is going at some of these key health systems
Can you put this in the context relative to the total number of retail locations you hope to be stocked at
Can you give any color on the new starts that are coming from the patients who had previously been on a CFTR modulator